microsatillite instability in crc henry t. lynch, md jane f. lynch, bsn creighton university
DESCRIPTION
MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University School of Medicine Omaha, Nebraska. Colorectal Cancer. Worldwide estimates for colorectal cancer during 2008*: Incidence – 1,233,711 Mortality – 608,644 - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/1.jpg)
1
MICROSATILLITE INSTABILITY IN CRC
HENRY T. LYNCH, MDJANE F. LYNCH, BSN
Creighton UniversitySchool of MedicineOmaha, Nebraska
![Page 2: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/2.jpg)
2
Colorectal CancerWorldwide estimates for colorectal cancer during 2008*:Incidence – 1,233,711 Mortality – 608,644
Worldwide estimates for familial/hereditary CRC during 2008*:Lynch syndrome 3-5% of all CRC 37,011-61,686FAP <1% of all CRC <12,337Familial 20% of all CRC 246,742
*GLOBOCAN. The International Agency for Research on Cancer web site. URL: http://www.iarc.fr/
![Page 3: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/3.jpg)
3
3
Familial/Hereditary CRC in US
Annual CRC incidence in US: 142,570
Lynch syndrome 3-5% of all CRC 4,277 - 7,129
FAP <1% of all CRC <1,426
Familial 20% of all CRC 28,514
Jemal et al. CA Cancer J Clin 60:277-300,2010.
![Page 4: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/4.jpg)
4
Magnitude of the Problem
Question: Why are these figures of such significant public health impact?
Answer: Each hereditary cancer comes from a family that could benefit immensely from genetic counseling.
DNA testing, surveillance, and highly-targeted management are the key!
Problem: Significance of family frequently missed!
![Page 5: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/5.jpg)
5
Should we test all colorectal cancer for
Lynch Syndrome?
YES! Test everybody.
![Page 6: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/6.jpg)
6
Search for LS Among CRC Affecteds*Evidence:Among 500 CRC patients, 18 (3.6%) had LS.
Of these 18: 18 (100%) had MSI-H CRCs; 17 (94%) were correctly predicted by IHC; only 8 (44%) were dx < 50 years; only 13 (72%) met the revised Bethesda guidelines; 1/35 cases of CRC show LS.
*Hampel et al. J Clin Oncol 26:5783-5788, 2008.
![Page 7: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/7.jpg)
7
Molecular Genetic Screening for LS
Recommendation*:All incident CRC and EC cases should be molecularly screened for LS.
MSI highly sensitive (89.3%).
IHC equally sensitive (91.2%), is inexpensive, is more readily available, and predicts the nonworking gene.
IHC is preferred method to screen for LS*.
*Hampel et al. J Clin Oncol 26:5783-5788, 2008.
![Page 8: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/8.jpg)
8
Familial CRC
Familial clustering of CRC, like that for carcinoma of the breast and stomach, has been discussed for more than 100 years.
What does it mean from the standpoint of risk?Best answer – First- degree relative of CRC affected has 2-3 fold excess risk for CRC compared to population expectations.
![Page 9: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/9.jpg)
9
Cardinal Features of Lynch Syndrome
• AD – MMR mutations• Proximal• Earlier age of onset• Accelerated carcinogenesis • Extra colonic cancers• Pathology – distinctive?• ↑ survival
![Page 10: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/10.jpg)
10
Increased risk for certain extracolonic malignancies
Endometrial Ovary Stomach Small bowel Pancreas Liver and biliary tree Muir-Torre cutaneous features Brain, (glioblastoma) – Turcot’s syndrome Possible Prostate cancer and others Breast cancer - controversial.
![Page 11: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/11.jpg)
11
Cardinal Features of Lynch Syndrome• Differentiating pathology features of LS CRCs:
- more often poorly differentiated;- excess of mucoid and signet-cell features;- Crohn’s-like reaction;- medullary features;- significant excess of infiltrating lymphocytes
within the tumor.
• Increased survival from CRC.
• Sine qua non for diagnosis is identification of germline mutation in MMR gene (most commonly MLH1, MSH2, MSH6) segregating in the family.
![Page 12: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/12.jpg)
A B
C D
![Page 13: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/13.jpg)
![Page 14: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/14.jpg)
Bethesda Guidelines and MSI Testing
MSI-H findings are associated with a moderate degree of uncertainty.
Such patients with MSI-H will merit referral for further genetic assessment.
Centers of expertise recommend informed consent for MSI testing.*
BRAF mutation, if present, will negate an LS diagnosis.
*Palomaki et al. Genet Med 11:42-65, 2009.
14
![Page 15: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/15.jpg)
15
Cost-effectiveness of DNA Testing
Estimate of the cost-effectiveness of genetic testing strategies to identify LS among newly dx CRC patients using MSI and IHC is cost-effective.* *Mvundura et al. Genet Med 12:93-104, 2010.
![Page 16: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/16.jpg)
16
Amsterdam CriteriaAC-I (24) At least three relatives with histologically verified colorectal cancer;
1.One is a first-degree relative of the other two;2.At least two successive generations affected;3.At least one of the relatives with colorectal
cancer diagnosed at <50 years of age;4.Familial adenomatous polyposis (FAP) has
been excluded.
![Page 17: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/17.jpg)
17
Amsterdam Criteria~ 60% of Amsterdam + Families have MSI-H and MMR mutations.
![Page 18: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/18.jpg)
18
Familial CRC Type “X”
Amsterdam Criteria positive but lacking MSI and MMR mutations will constitute ~ 40% of those AC-I without MMR mutations and therein referred to as familial CRC type X.*
1) CRC > left side2) CRC and extra colonic CRC3) Later age CRC onset4) Molecular genetics (MSI and IHC or MMR mutation) ABSENT!
*Lindor et al. JAMA 293:1979-1985, 2005.
![Page 19: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/19.jpg)
19
Epithelial Cell Adhesion Molecule (EPCAM) Gene and Its Lynch Syndrome Connection*
A portion of this ~40% lacking MMR mutations is caused by a mutation mechanism in the gene known as EPCAM.
*Kovacs et al. Hum Mutat 30:197-203, 2009.
![Page 20: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/20.jpg)
20
Polyadenylation Sequence
5’ EPCAM deletion Exons 8 and 9 and polyadenylation sequence
Ligtenberg MJ, Nature Genetics 2009.
Transcriptional read throughHypermethylation of the MSH2 promoter
![Page 21: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/21.jpg)
21
Why LS with Site-Specific CRC?
Deletion in EPCAM results in hypermethylation and incomplete silencing of MSH2.
EPCAM mutation carriers may have phenotypic features that differ from carriers of MSH2 mutations – namely, an almost exclusive expression of site-specific CRC, thereby lacking extracolonic cancers.
![Page 22: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/22.jpg)
22
c.859-1462_*1999del (4.9 kb, starting in intron 7 and including exons 8 & 9)
EPCAM MSH2
American and Dutch families have the same deletion in the EPCAM gene
Deletion
Lightenberg, Nature Genetics 2009.
![Page 23: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/23.jpg)
23
American and Dutch EPCAM mutations originate from a common ancestor
Deletion and Region inherited from
common ancestor
Family R and the Dutch families share a 6.1 MB region surrounding the same EPCAM deletion indicating a common ancestor. Based on the size of the
shared region it is estimated the deletion occurred 10 generations ago.
Dutch Families
Chromosome 2
Family R
Chromosome 2
![Page 24: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/24.jpg)
24
History of Family R*
Ascertained by us in 1970 and followed continuously.
700 blood line relatives
327 individuals age ≥ 18, ≥ 25% pedigree risk
Phenotype strikingly similar to LS but integral extracolonic cancers absent (site-specific CRCs)
*Lynch et al. Cancer 56:934-938, 1985. Lynch et al. Cancer 56:939-951, 1985.
![Page 25: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/25.jpg)
25
First patient identified with EPCAM mutation
CRC affecteds EPCAM results
![Page 26: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/26.jpg)
26
MSI in CRC*Microsatellite instability (MSI): a) is hypermutable phenotype due to loss of DNA MMR activity; b) is present in ~ 15% of all CRCs; c) ~ 3% associated with LS, remaining 12% sporadic acquired hypermethylation of promoter of MLH1 gene; d) occurs in tumors manifesting the CpG island methylator phenotype.
* Boland and Goel. Gastroenterology 138:2073-2087, 2010.
![Page 27: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/27.jpg)
What Is MSI?*
Nearly all LS tumors differ from their sporadic counterparts and most are characterized by MSI.
MSI mutations occur at short repetitive sequences called microsatellites. Most are insertion or deletion mutations and, as a consequence of loss of DNA MMR activity.
*Boland & Goel. Gastroenterology 138:2073-2087, 2010.
27
![Page 28: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/28.jpg)
Definitions of MSI’s Dx Criteria
These comprise BAT-25 and BAT-26 mononucleotides and D5S346, DS123, and D12S250 dinucleotide repeats.
> 2 or more markers → MSI-H;
those with one unstable marker MSI-L;
those absent instability referred to as MSS.
28
![Page 29: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/29.jpg)
BRAFV600E Mutations in MSI*
The BRAFV600E mutation occurs exclusively in sporadic forms of MSI CRC.
Combined analysis of MSI and BRAFV600E mutation is included in current protocols of LS since it is a reliable, fast, and low-cost strategy.
Helps identify sporadic cases and avoids time-consuming and expensive screening of MMR germline mutation analysis.
*Seruca et al. Expert Rev Gastroenterol Hepatol 3:5-9, 2009.
29
![Page 30: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/30.jpg)
Algorithm
1. IHC on all colorectal patients on tumor block;
2. If positive, BRAF (if positive, then sporadic);
3. Only do full MMR genetic tests on patient IHC +. BRAF neg.
30
![Page 31: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/31.jpg)
31
MORPHOLOGYSUSPICIOUS
FOR MSI-H
Run PCR testfor MSI status
Is thereMSI-H?
Run mutation analysisfor BRAF V600E
Is thereBRAF V600E
mutation?
SPORADIC CRCWITH MSI-H
NO EVIDENCE OFLYNCH
SYNDROME
Is there lossof stainingwith any ofthe Abs?
IHC for MLH1,MSH2, MSH6, PMS2
PUTATIVELYNCH
SYNDROME
MMR GENES MUTATIONANALYSIS
Is therea mutation in MMR
gene?
LYNCHSYNDROME
YES
YES
NO
NO
NO
YES
YES
NO
Gatalica Z, Torlakovic E. Fam Cancer 2008;7:15-26
FAMILIAL CRCTYPE “X”
![Page 32: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/32.jpg)
MSI Analysis
A functional assay for the MMR proteins
![Page 33: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/33.jpg)
MSI Analysis
![Page 34: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/34.jpg)
![Page 35: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/35.jpg)
![Page 36: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/36.jpg)
MSI High Data
New – Focus on Mononcleotides
![Page 37: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/37.jpg)
MSI and Therapeutic Implications
Pharmacogenetics:
5-FU-based chemotherapy refractory in MSI CRCs;
possible advantage of irinotecan-based therapy;
the latter “not ready for prime time” but 5-FU approaching clinical acceptability.
Boland and Goel. Gastroenterology 138:2073-2087, 2010.
37
![Page 38: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/38.jpg)
MSI and Therapeutic Implications*
Where did this knowledge originate?Through DNA MMR genes first identified in
bacteria through exposure to cytotoxic mutagens (alkylating agents) and selecting for strains resistant to DNA damage.
*Carethers et al. J Clin Invest 98:199-206, 1996. Ribic et al. N Engl J Med 349:247-257, 2003.
38
![Page 39: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/39.jpg)
MSI and Therapeutic Implications*
Resulting bacteria were hypermutable and resistant to DNA alkylation.
Resistant to cytotoxic agents that acted by damaging DNA.
Raised possibility that DNA MMR deficient cells might be relatively resistant to some types of cytotoxic chemotherapy.
*Carethers et al. J Clin Invest 98:199-206, 1996. Ribic et al. N Engl J Med 349:247-257, 2003.
39
![Page 40: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/40.jpg)
MSI and Therapeutic Implications
Virtually all studies show either no benefit or adverse effects in response to 5-FU-based adjuvant chemotherapy (reviewed by Boland and Goel.*)
In vitro responses suggest that chemoresistance is seen for many chemotherapeutic agents.**
*Gastroenterology 138:2073-2087, 2010.**Aebi et al. Cancer Res 56:3087-3090, 1996.
40
![Page 41: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/41.jpg)
MSI and Therapeutic Implications*
Currently, guidelines do not recommend using MSI status to determine whether or not to use chemotherapy.
This recommendation merits a second look, given the wealth of data showing the inadequacy of 5-FU for CRC with MSI.
Should be tested only in the context of a randomized clinical trial.
*Boland & Goel. Gastroenterology 138:2073-2087, 2010.
41
![Page 42: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/42.jpg)
Immune Response in CRCs with MSI
CRCs with MSI demonstrate a host-immune response characterized by tumor infiltrating lymphocytes (TILs):
• may exert effects on tumor cell apoptosis and cell proliferation;
• associated with improved disease-free survival;
*Sinicrope et al. Int J Cancer 120:1232-1238, 2007.
42
![Page 43: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/43.jpg)
Immune Response in CRCs with MSI
(continued:)• Apoptosis/proliferation ratios and reduced cell
proliferation;• Phenotypic features of MSI-H tumors, associated
with ↑ TILs;• Indicate an activated immune response that may
contribute to their favorable survival rates.
*Sinicrope et al. Int J Cancer 120:1232-1238, 2007.
43
![Page 44: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/44.jpg)
Host Immune Response Characterized by Tumor Infiltrating Lymphocytes (TILs)*
Summary:Higher apoptosis/proliferation ratios and reduced
cell proliferation are phenotypic features of MSI-H tumors that are associated with ↑ TILs;
Indicating an activated immune response, and may contribute to their favorable survival rates.
*Sinicrope et al. Int J Cancer 120:1232-1238, 2007.
44
![Page 45: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/45.jpg)
IHC and LSIHC is an acceptable substitute for MSI, given
strong concordance rates of 94% between MSI and IHC in CRC and EC.*
Allows gene-specific DNA analysis based on staining pattern.
MMR protein deficiency occurs in 12-20% of CRCs.**
*Palomaki et al. Genet Med 11:42-65, 2009.**Hampel et al. J Natl Comp Cancer Net 8:597-
601, 2010.
45
![Page 46: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/46.jpg)
46
Targeted CRC Screening
Screening is melded to LS’s natural history:
Proximal location colonoscopy
Early age of onset beginning at age 25
Accelerated carcinogenesis every 1-2 yrs < age 40, then annually
Pattern of extra-colonic cancers targeted screening
![Page 47: MICROSATILLITE INSTABILITY IN CRC HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University](https://reader036.vdocuments.site/reader036/viewer/2022062323/5681653b550346895dd7bb6b/html5/thumbnails/47.jpg)
47
MSI/IHC in CRC*Conclusion:CRCs with MSI may show distinctive clinical, pathologic features: a) predominance of CRC in proximal colon; b) lymphocyte infiltration within tumor; c) poorly differentiated mucinous or signet cell appearance; d) better prognosis; e) differing response to chemotherapeutics; f) molecular screening all CRC cases.
*Boland and Goel. Gastroenterology 138:2073-2087, 2010.